Senores Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rjao8x4iy0gle9iauhtlmvwp.pdf

Key Takeaways


The Commercialization Backlog

The quarter’s defining feature was not what shipped but what sits approved and unlaunched. The company holds 41 approved ANDAs yet to be commercialized, plus 43 pipeline ANDAs, for a total of 84 products to roll out over the next 2–4 years. In emerging markets, 944 filed registrations await approval, expected to convert over the next 2–4 quarters. Management cautioned that the pace cannot be modeled as a simple quarterly division because regulatory processes, quota applications, and distributor sell-in cycles sit outside its control.

Sanjay Majmudar: "And it can't happen at, you know, divide by the number of quarters. It has to be looked at on a more broader time frame of maybe 6 to 12 months, because many things are not under our control."

Subsidiary Activation: Amerisyn & Zoraya

Two acquisitions are incurring operating costs inside the P&L with no revenue offset, making their activation the single largest near-term margin and growth lever. Both are expected to go live imminently, and management stated that once revenues begin, existing operating costs will be easily absorbed, and they do not expect any margin dip, but will continue to monitor how margins progress.

Swapnil Shah: "Difficult to pinpoint. I mean, the direction is there as you stated. But till both the subsidiaries are operationalized to a level that we would like it to be, commenting whether the margin will further strengthen beyond what they are today will be a little tough."

Apnar Facility: Full Machines, Half Revenue

The Apnar injectables facility is running at 90–100% capacity, but more than half of that capacity is consumed by validation work for future product launches rather than revenue-generating production. Revenue of approximately INR21 crores in Q2 came largely from the five ANDAs acquired with the facility.

Swapnil Shah: "So, it's almost at peak, I would say, that the utilization is there. But the complete utilization is not generating in the revenue as yet. Since there's lot of validation work, more than 50% validation work is going on."

Emerging Markets: Margin Volatility Masks Structural Shift

Emerging-market revenue grew ~21% in Q2 and 25% in H1, and the business has turned cash positive. But Q2 margins dipped because of a product-mix swing: there were few large orders of beta-lactam products, which are relatively high-price antibiotics in a competitive landscape. Management urged investors to view the segment on a longer horizon, and October trends already point to a rebound toward the mid-to-late teens.

Sanjay Majmudar: "See, quarterly run rate is very difficult to maintain because the business does not happen the way we want actually. So, I think you should look at us on a little longer horizon as Swapnil said. It should be maintained. Don't worry about it."

Regulated Markets: First-to-Launch Products Lift Realizations

Regulated-market revenue grew 28% Y-o-Y in Q2 and 34% in H1, with the ANDA portfolio nearly doubling from 34 to 64. Sequential EBITDA margin improvement was driven primarily by new launches with good realization, especially first-to-launch products in the US, which carry structurally higher margins.

Swapnil Shah: "Do we expect it to go down? The answer is no, if that is the question you'll be asking."

Pipeline Breadth Beyond ANDAs

The company is building growth levers that extend beyond the core ANDA portfolio, with several initiatives approaching revenue inflection in H2 FY27 and beyond.


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growth30% to 40% Y-o-YFY27 full year
FY27 PAT growth50% to 60% Y-o-YFY27 full year
FY27 EBITDA margin30% plus, definitely not 28%FY27 full year
Amerisyn commercialization startWithin 10–15 days from Oct 29, 2026Mid-November 2026
Zoraya commercialization startWithin current quarter; worst case ~45 days from Oct 29, 2026By mid-December 2026
Amerisyn product launchesMore than 10 productsNext two quarters
Zoraya ANDA launches14 ANDAsFY27
Controlled substance ANDA launchFirst product launch by November endQ3 FY27
Controlled substance launches4–5 productsBefore March 31, 2027
Q3 ANDA approvals3–4 new ANDAs and 12–15 sANDAsQ3 FY27
Apnar commercial lines4 lines, ~120 crore units capacityBy March 31, 2027
Apnar revenue contribution~INR100-odd crores plusFY27
Apnar new product commercializationFilings begin commercializingNovember/December 2026 onward
Emerging markets full-year marginMid-teens to lower teensFY27
Emerging markets near-term marginMid-teens to later teensNext two quarters
Branded generics revenueINR50–60 crores with >60% gross marginFY27
Approved ANDA commercialization41 approved but unlaunched ANDAsNext 6–8 quarters
Total ANDA commercialization84 ANDAs (41 approved + 43 pipeline)Next 2–4 years
Emerging market registration approvals944 filed registrationsNext 2–4 quarters
Beyond-FY27 revenue growth~25% annual growthNext 2–3 years
Bottom-line vs top-line growthPAT growth to exceed revenue growthFY27

Key Metrics

MetricQ2 FY27
Revenue₹192 cr, +25% YoY, highest-ever quarterly revenue
EBITDA₹58 cr, +38% YoY
EBITDA margin30%, +290 bps YoY; operating EBITDA, reported EBITDA higher due to other income
PAT₹36.6 cr, +22% YoY
H1 FY27 revenue₹372.5 cr, +30% YoY
H1 FY27 EBITDA₹111 cr, +58% YoY
H1 FY27 EBITDA margin~30%, +530 bps YoY
H1 FY27 PAT₹67 cr, +31% YoY
FY27 revenue growth guidance30% to 40%, maintained
FY27 PAT growth guidance50% to 60%, maintained
Beyond FY27 annual growth guidance~25% over next 2 to 3 years
Regulated market revenue growth+28% YoY in Q2, +34% in H1 FY27
Emerging market revenue growth~21% YoY in Q2, +25% in H1 FY27
Approved ANDAs64 as of Sep 2026, up from 34 in Sep 2025; 23 commercialized
ANDAs commercialized in Q23 sANDAs (4 strengths), 3 CDMO ANDAs (12 strengths); 1 new ANDA approved, launch in Q3
CDMO CMO share of regulated market revenue~35%
Apnar facility revenue₹21 cr in Q2; on track for ₹100 cr+ in FY27
Apnar capacity utilization90% to 100%, with over 50% on validation work
Emerging markets H1 FY27 EBITDA margin~10%; full-year expected mid to lower teens
Branded generics India gross margin>60% in FY27, up from 18% to 20% last year on similar scale
Zoraya and Amerisyn pre-revenue costs in Q2~₹4 cr, recognized in P&L with no corresponding revenue
Operating cash flow₹38 cr in H1 FY27
Capex~₹46 cr in H1 FY27
Emerging markets registrations558 approved, 944 filed awaiting approval
Zoraya planned ANDA launches in FY2714